Two major partnerships announced this week show how scientific publishers and AI platforms are collaborating to accelerate drug discovery by making research literature more accessible to artificial intelligence systems. Sage Publishing has licensed its journal content to Causaly, an AI platform for biomedical research, while Tokyo-based Elix is partnering with the University of Vienna to combine AI-driven molecular design with experimental structural biology.

What's Changing in How Researchers Access Scientific Literature?

The Sage-Causaly partnership marks a shift in how AI systems interact with published research. Rather than training AI models on journal content, the deal uses a technique called retrieval augmented generation, or RAG. This approach allows Causaly's AI agents to search through the full text of approximately 400 Sage journals, including methods, results, tables, and supplemental data, then surface the most relevant findings directly within researchers' workflows.

Katie Metzler, vice president of Sage's global licensing team, explained the distinction between different types of AI licensing. "There are two kinds of AI licensing," she stated. "There's licensing for training, where the content is used to train the underlying model. Then there's licensing for RAG, which does not allow training of the underlying foundation model but instead allows the licenser to create a vector database of the content".

"With Sage content deeply integrated inside Causaly's agentic AI platform, we can extend our reach and impact where researchers do their important work. Access and intelligence go hand in hand, and this partnership puts them in one place," said Bob Howard, executive vice president of global journals at Sage.

Bob Howard, Executive Vice President of Global Journals at Sage

The partnership is now available to all Causaly customers as an add-on to their platform subscription. Sage subscribers can link directly from Causaly's extracted evidence view to the full article on Sage's website. Customers without a Sage subscription can view a snapshot of the article and purchase it through Causaly.

How Are Publishers and AI Platforms Learning to Work Together?

Both Sage and Causaly are entering this partnership as a learning opportunity. The publishing industry is still figuring out what effective partnerships with AI platforms should look like. One key concern is the "zero-click world" scenario, where researchers get answers directly from the AI tool and never click through to read the full paper, potentially reducing traffic to publisher websites.

Metzler acknowledged that there is also potential for new value creation. "There is also the possibility that this generates a new value that could drive traffic from places that we're not currently realizing that value," she noted. "We need to learn about what this new discovery path looks like".

Metzler

The Sage deal is not the publisher's first venture into AI partnerships. In January 2026, Sage struck a similar partnership with Consensus, another AI workspace for scientific research based in San Francisco. Sage also strengthened its biomedical publishing portfolio in 2025 by acquiring Mary Ann Liebert, the founding publisher of Genetic Engineering and Biotechnology News, which publishes more than 100 peer-reviewed titles included in the new Causaly partnership.

How Are AI and Structural Biology Combining to Target "Undruggable" Diseases?

In a separate development, Elix, a Tokyo-based AI drug discovery company, has signed a joint research agreement with the University of Vienna to tackle diseases that have historically resisted traditional drug discovery approaches. The collaboration merges Elix's AI-driven molecular generation capabilities with the Orts Lab's expertise in nuclear magnetic resonance, or NMR, spectroscopy, a technique that reveals atomic-level details of how proteins behave.

The research group, led by Julien Orts at the University of Vienna, specializes in understanding protein dynamics and interactions at atomic resolution. Their work includes developing methods like INPHARMA, which validates how small molecules bind to proteins, and using exact nuclear Overhauser enhancement distance measurements with 0.1 angstrom accuracy to resolve protein ensembles.

"We are thrilled to partner with Elix to bridge the gap between advanced structural biology and artificial intelligence. By combining our ability to resolve protein dynamics at atomic precision with Elix's sophisticated AI-driven generation, we can move beyond static structures and begin to target the complex, transient behaviors of proteins that were once considered out of reach," said Julien Orts.

Julien Orts, Associate Professor at the University of Vienna

The partnership specifically targets intrinsically disordered proteins, or IDPs, and proteins involved in epigenetic signaling and cancer. These protein types have been notoriously difficult to drug because they lack stable three-dimensional structures. By integrating AI's predictive power with experimental atomic-resolution data, the researchers aim to bypass traditional limitations and discover new therapeutic candidates for complex diseases.

Ways AI Drug Discovery Platforms Are Evolving to Support Researchers

• Full-Text Integration: AI agents can now digest complete peer-reviewed papers, including methods, results, tables, and supplemental data, rather than relying on abstracts or titles alone, providing researchers with comprehensive evidence for their work.
• Intuitive User Interfaces: Elix Discovery and similar platforms feature graphical user interfaces designed specifically for medicinal chemists, automatically constructing predictive models and generating novel molecular structures that humans might not conceive independently.
• Hybrid Experimental-Computational Approaches: New partnerships combine AI-driven molecular generation with experimental techniques like NMR spectroscopy, enabling researchers to target previously "undruggable" proteins by understanding their dynamic behavior at atomic resolution.
• Rights-Compliant Content Access: RAG licensing deals ensure that AI platforms can access published research while protecting author rights and publisher interests, avoiding the broad copyright exceptions that some worry could undermine academic publishing.

Shinya Yuki, CEO of Elix, emphasized the company's mission to bridge AI and experimental innovation. "Collaborating with the Orts group allows us to pursue this mission on a global scale, uniting expertise in AI drug discovery with structural biology. We believe this partnership will open new possibilities for targeting diseases that have long remained beyond the reach of traditional drug discovery," he stated.

Shinya Yuki, CEO of Elix

What Are the Broader Implications for Drug Discovery?

These partnerships reflect a fundamental shift in how drug discovery research is conducted. Rather than researchers starting their work on journal platforms or Google search pages, they increasingly begin with AI-powered natural language tools that synthesize and surface relevant findings. This change requires publishers, AI platforms, and researchers to rethink how discovery workflows function and how value flows through the system.

Metzler noted that the industry still has concerns to address. Some authors worry about their content being used in AI systems without proper compensation or attribution. "People hear AI and think of big tech companies gobbling everything up without permission or payment, using it to train their large language models and then capturing all that value for themselves and not giving any of that back," she acknowledged. The RAG licensing model, by contrast, ensures that publishers and authors are compensated when their content is accessed through AI platforms.

Metzler

As these partnerships mature, both publishers and AI platforms will learn how AI-mediated discovery affects research workflows, usage patterns, and the ultimate pace of scientific breakthroughs. The Sage-Causaly and Elix-University of Vienna collaborations represent early steps in what is likely to become a much larger transformation in how biomedical research is conducted and how drug candidates are discovered and developed.